JPH03195563A - Chemical injection system - Google Patents
Chemical injection systemInfo
- Publication number
- JPH03195563A JPH03195563A JP1337680A JP33768089A JPH03195563A JP H03195563 A JPH03195563 A JP H03195563A JP 1337680 A JP1337680 A JP 1337680A JP 33768089 A JP33768089 A JP 33768089A JP H03195563 A JPH03195563 A JP H03195563A
- Authority
- JP
- Japan
- Prior art keywords
- connector
- catheter
- intermediate tube
- tube
- metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 20
- 239000007924 injection Substances 0.000 title claims abstract description 20
- 239000000126 substance Substances 0.000 title abstract description 6
- 229910052751 metal Inorganic materials 0.000 claims abstract description 25
- 239000002184 metal Substances 0.000 claims abstract description 25
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000004033 plastic Substances 0.000 claims abstract description 6
- 229920003023 plastic Polymers 0.000 claims abstract description 6
- 239000010936 titanium Substances 0.000 claims abstract description 6
- 229910052719 titanium Inorganic materials 0.000 claims abstract description 6
- 229920002635 polyurethane Polymers 0.000 claims abstract description 4
- 239000004814 polyurethane Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 47
- 229940079593 drug Drugs 0.000 claims description 46
- 230000002785 anti-thrombosis Effects 0.000 claims description 12
- 239000003146 anticoagulant agent Substances 0.000 claims description 7
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 22
- 210000004204 blood vessel Anatomy 0.000 abstract description 13
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004721 Polyphenylene oxide Substances 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract description 2
- 229960002897 heparin Drugs 0.000 abstract description 2
- 229920000669 heparin Polymers 0.000 abstract description 2
- 229920000570 polyether Polymers 0.000 abstract description 2
- 229920002379 silicone rubber Polymers 0.000 abstract description 2
- 239000004945 silicone rubber Substances 0.000 abstract description 2
- 229910001220 stainless steel Inorganic materials 0.000 abstract description 2
- 239000010935 stainless steel Substances 0.000 abstract description 2
- 230000002965 anti-thrombogenic effect Effects 0.000 abstract 3
- -1 e.g. Substances 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 230000008901 benefit Effects 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、動脈及び静脈血管に薬剤を注入するための体
内埋め込み式薬剤注入システムに関するものであり、さ
らに、詳しくは、体内に埋め込んで使用するに際して、
磁気診断装置の磁力の影響を受けず、また、該診断装置
の診断に影響を与えない上、数箇月に及ぶ長期間の体内
留置においても材質の変化及び組織との反応性がなく、
抗血栓性においても良好な薬剤注入システムに関するも
のである。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to an implantable drug injection system for injecting drugs into arterial and venous blood vessels, and more specifically, to a system for injecting drugs into arteries and veins. In doing so,
It is not affected by the magnetic force of the magnetic diagnostic device, does not affect the diagnosis made by the diagnostic device, and does not change its material or react with tissues even when left in the body for several months.
The present invention relates to a drug injection system that also has good antithrombotic properties.
［従来の技術］
従来より、薬剤リザーバーとカテーテルよりなる体内埋
め込み式の薬剤注入用カテーテルは、体外に露出した薬
剤供給口がないので、種々の雑菌による感染が防止でき
る利点から広く使用され始め ｔこ 。[Prior Art] Conventionally, catheters for injecting drugs implanted into the body, which are composed of a drug reservoir and a catheter, have started to be widely used because they have no drug supply ports exposed outside the body and can prevent infections caused by various bacteria. child .
注射針の穿刺部付き薬剤リザーバーを手術により体内に
埋め込み、この穿刺部よりリザーバーに定期的に薬剤な
どを仕込み、リザーバーに取り付けたチューブを経由し
て、所定の動脈又は静脈に継続的に供給するシステムは
行われている。A drug reservoir with a punctured part of a syringe needle is surgically implanted into the body, and drugs are periodically loaded into the reservoir from this punctured part and continuously supplied to a designated artery or vein via a tube attached to the reservoir. The system is done.
この場合、血管の中に挿入されるチューブの先端部は、
抗血栓性であることが必要であり、先端部に達するまで
の中間のチューブはこれが接する体内組織と反応性のな
いものが必要であり、チューブか両方の特性を有するも
のが必要である。In this case, the tip of the tube inserted into the blood vessel is
It is necessary to have antithrombotic properties, and the intermediate tube leading up to the distal end must be non-reactive with the body tissue it comes into contact with, and a tube that has the characteristics of both is required.
チューブ材質の組織適合性と抗血栓性はよく似ているが
、一方の性能が良好でも他方の性能が必ずしも良好とは
限らない。Although the tissue compatibility and antithrombotic properties of tube materials are very similar, good performance in one does not necessarily mean good performance in the other.
長い場合には数箇月間埋め込まれる薬剤供給システムで
は、材質として両者ともに優れていることを必要とする
。A drug delivery system that is implanted for a long period of time, sometimes several months, requires excellent materials of both types.
さらに、従来の該システムでは、注射針の突き抜けの危
険性を回避するためにリザーバーにステンレス銅等の金
属か使用されることが多く、このような磁性金属を使用
した場合、長時間の埋め込み期間中に、ＭＨＩなどの強
力な磁気をかける診断を行う場合に、磁気診断に悪影響
を与えたり、埋め込み薬液リザーバーが強力な磁力によ
り移動して、先端部が血管から脱落する不都合が生じる
。Furthermore, in conventional systems, metals such as stainless copper are often used for the reservoir to avoid the risk of needle penetration, and when such magnetic metals are used, long implantation periods are required. When performing a diagnosis that applies a strong magnetic field, such as MHI, there is a problem that the magnetic diagnosis is adversely affected or the implanted drug reservoir is moved by the strong magnetic force, causing the distal end to fall out of the blood vessel.
［発明が解決しようとする課題］
本発明は、体内に埋め込んだ場合に体内組織適合性と抗
血栓性がともに優れ、磁気診断に悪影響のない体内埋め
込み式薬剤供給カテーテルを提供するものである。[Problems to be Solved by the Invention] The present invention provides an implantable drug delivery catheter that has excellent tissue compatibility and antithrombotic properties when implanted in the body, and has no adverse effect on magnetic diagnosis.
［課題を解決するための手段］
本発明者らは、チューブ中間部分の体内組織適合性とチ
ューブ先端部分の抗血栓性を達成するために、チューブ
の材質を途中で変更する方法が最適と思考して、先端の
血管内に挿入される部分のチューブを抗血栓性材料とし
て、リザーバーから血管に挿入される前までのチューブ
を組織適合性材料で形成し、リザーバー容器を非磁性金
属にすることにより、上記課題を達成した。[Means for Solving the Problems] The present inventors believe that in order to achieve in-vivo tissue compatibility in the middle portion of the tube and antithrombotic properties in the tip portion of the tube, it is optimal to change the material of the tube midway through. The tube at the distal end to be inserted into the blood vessel is made of antithrombotic material, the tube from the reservoir to before being inserted into the blood vessel is made of tissue compatible material, and the reservoir container is made of non-magnetic metal. As a result, the above objectives were achieved.
すなわち、本発明は、薬剤リザーバー、中間チューブ、
コネクター及び先端カテーテルを必須構成要素とする体
内埋め込み式カテーテルにおいて、薬剤リザーバーは、
上面に軟質材料製穿刺部を有する非磁性金属製の流出口
付き容器であって、中間チューブは、組織適合性表面を
有して流出口どコネクターを連結し、コネクターは非磁
性金属製又は硬質プラスチック製であって中間チューブ
と先端カテーテルを連結し、先端カテーテルは抗血栓性
表面を有することを特徴とする薬剤注入システムを提供
するものである。That is, the present invention provides a drug reservoir, an intermediate tube,
In an implantable catheter that includes a connector and a tip catheter as essential components, the drug reservoir is
A container with an outlet made of non-magnetic metal and a puncture part made of a soft material on the upper surface, the intermediate tube having a tissue-compatible surface to connect the outlet connector, and the connector made of non-magnetic metal or a hard material. The present invention provides a drug injection system which is made of plastic and which connects an intermediate tube and a distal catheter, the distal catheter having an antithrombotic surface.
本発明システムは、第１図に示すように、薬剤リザーノ
パ−１、中間チューブ２、コネクター３及び先端カテー
テル４を必須構成要素とする体内埋め込み式カテーテル
であり、薬剤リザーバー１は、注射針による穿刺注入部
である自己密閉型セプタム７を有する金属容器であって
、本体容器部分が非磁性金属製である以外は従来使用さ
れている埋め込み火薬剤リザーバーと同−形状及び同一
機能のものを特に制限なく使用することができる。As shown in FIG. 1, the system of the present invention is an implantable catheter in the body that includes a drug reservoir 1, an intermediate tube 2, a connector 3, and a distal catheter 4 as essential components. Metal containers with a self-sealing septum 7, which is the injection part, and which are the same in shape and function as conventionally used embedded explosive reservoirs, except that the main container part is made of non-magnetic metal, are particularly restricted. It can be used without.
本発明薬剤リザーバーの容器内に２個以上の穿刺部と２
個以上の薬剤室を設け２種以上の薬剤を供給することが
できる。Two or more puncture parts and two puncture parts are provided in the container of the drug reservoir of the present invention.
It is possible to provide two or more drug chambers and supply two or more types of drugs.
この容器部分が金属であることは、薬剤補給の際に注射
針が突き抜けないためとＸ線による検知ができる利点か
ある。The fact that this container part is made of metal has the advantage that the injection needle cannot be penetrated when replenishing the medicine and that it can be detected by X-rays.
本発明においては、該金属か非磁性金属、例えば、高純
度チタン、非磁性ステンレスなどによって製造されたも
のである点に特徴がある。The present invention is characterized in that the metal is manufactured from a non-magnetic metal, such as high-purity titanium or non-magnetic stainless steel.
非磁性金属を使用することにより、ＮＭＲ診断などの場
合に強力な磁力によって、リザーバーが移動したり、回
転して、注入チューブの先端が血管から抜ける危険を防
止することができる。By using a non-magnetic metal, it is possible to prevent the reservoir from moving or rotating due to strong magnetic forces such as in NMR diagnosis, thereby preventing the risk of the distal end of the injection tube coming out of the blood vessel.
非磁性金属の中でも、純度９９％以上の高純度金属チタ
ンがとくに本発明の薬剤リザーバーの材質として優れて
いる。Among non-magnetic metals, high-purity titanium metal with a purity of 99% or more is particularly excellent as a material for the drug reservoir of the present invention.
高純度チタンは、体内に長期間留置しても体内組織に影
響が全くなく、しかも、鉄などと比較すると密度が１／
２であり、軽量であるので埋め込み部の組織に負担をか
けない利点がある。High-purity titanium has no effect on body tissues even if left in the body for a long period of time, and has a density that is 1/2 that of iron.
2, and because it is lightweight, it has the advantage of not placing a burden on the tissue of the implanted part.
本発明システムにおいて、薬剤供給チューフハ中間チュ
ーブ２と先端カテーテル４に分かれ、両者をコネクター
３が連結している。In the system of the present invention, the drug supply tube is divided into an intermediate tube 2 and a distal catheter 4, which are connected by a connector 3.
本発明に用いる薬剤供給チューブは、２本以上の複数通
路を有する構造にして混合できない２種以上の薬剤又は
輸液を注入できるようにすることができる。The drug supply tube used in the present invention can have a structure having two or more multiple passages so that two or more types of drugs or infusions that cannot be mixed can be injected.
本発明に用いるコネクター３は、金属又は硬質のプラス
チック類にすることができる。金属の場合はＸ線により
所在が検知できて便利であるが、非磁性金属にする必要
かある点はりザーバー容器１の場合と同様の理由で必要
である。The connector 3 used in the present invention can be made of metal or hard plastics. If it is made of metal, it is convenient because its location can be detected by X-rays, but it is necessary to use non-magnetic metal for the same reason as in the case of the reservoir container 1.
また、プラスチック製コネクターにした場合には造影剤
をブレンドしたものを使用することができる。Furthermore, in the case of a plastic connector, a contrast agent blended therein can be used.
本発明のプラスチック製コネクターの材質としては、ポ
リカーボネート樹脂が適している。Polycarbonate resin is suitable as the material for the plastic connector of the present invention.
本発明コネクター３は、中空の管状であって、連結すべ
き両チューブの端５．６に挿入して嵌合させて連結する
。コネクター３の長さは連結固定強度があれば短いほど
よく、連結強度はコネクタの嵌合部に滑り止めの凹凸溝
を設けて達成することかできる。この場合、プラスチ／
り族コネクターを使用する場合は、両チューブの端５．
６をコネクターの上で円滑に重合させて連結部表面を円
滑曲面となるように被覆するのが組織反応防止の点から
望ましい。The connector 3 of the present invention has a hollow tubular shape, and is inserted into the ends 5.6 of both tubes to be connected, and the connectors 3 are fitted into the ends 5.6 of the tubes to be connected. The shorter the length of the connector 3, the better, as long as it has the connection and fixing strength, and the connection strength can be achieved by providing anti-slip grooves in the fitting portion of the connector. In this case, plasti/
If you are using a connector from the 5.
From the viewpoint of preventing tissue reaction, it is desirable to smoothly polymerize 6 on the connector so that the surface of the connecting portion is coated with a smoothly curved surface.
本発明コネクターも２種以上の薬剤を供給するために複
数の通路を設けたものを使用することができる。The connector of the present invention may also be provided with a plurality of passages for supplying two or more types of drugs.
このコネクターの位置は、患者によって相違する挿入部
と薬剤リザーバー保持部の距離及び血管内に入る先端カ
テーテルの長さに応じて、体内組織から血管に入る境界
近くに、適宜設定することかできる。The position of this connector can be appropriately set near the boundary where the catheter enters the blood vessel from the body tissue, depending on the distance between the insertion section and the drug reservoir holding section, which differs depending on the patient, and the length of the distal end catheter that enters the blood vessel.
本発明に用いる中間チューブ２は、組織適合性材料、例
えば、シリコンゴムなどの体内組織との反応性が殆どな
い材料を表面として使用する必要がある。The surface of the intermediate tube 2 used in the present invention must be made of a tissue-compatible material, for example, a material such as silicone rubber that has little reactivity with body tissue.
本発明においては、中間チューブ２全体を組織適合性材
料で製造するか、チューブの外面を組織適合性物質によ
りコーティング又は積層したものを使用することができ
る。In the present invention, the entire intermediate tube 2 may be made of a tissue-compatible material, or the outer surface of the tube may be coated or laminated with a tissue-compatible material.
中間チコーブの組織適合性材質としては、体内組織と反
応しないものほとよく、この観点からシリコーンが最適
である。As a tissue-compatible material for the intermediate chicove, it is best to use a material that does not react with body tissues, and from this point of view, silicone is most suitable.
本発明に用いる先端カテーテルは、血管内に導入されて
固定されるものであり、長期間血液と接触しているので
、チューブ先端の内外表面に血液凝固物が付着Ｉ７やす
く、このものが剥がれ落ちると血液の流れに乗って血管
内を移動する。これが肺塞栓、腎機能の低下などの原因
となる。このため先端チューブの内外表面は、抗血栓性
である必要かある。The tip catheter used in the present invention is introduced into a blood vessel and fixed, and as it is in contact with blood for a long period of time, blood clots are likely to adhere to the inner and outer surfaces of the tube tip and fall off. and moves within the blood vessels along with the flow of blood. This causes pulmonary embolism and decreased kidney function. For this reason, the inner and outer surfaces of the tip tube need to be antithrombotic.
本発明の先端カテーテルは抗血栓性物質、例えは、ンリ
フーン、ウレタンとシロキサンのブロックポリマー、ポ
リエーテル型ポリウレタンなどにより製造されたもの又
はこれらの物質若しくはヘパリン、ウロキナーゼなどの
生理活性物質を表面に局在化させた材料、特Ｃコヘバリ
ン化親水性材料などをコーティングしたものも使用する
ことができる。The tip catheter of the present invention is made of an antithrombotic substance, for example, one made of antithrombotic substances, block polymers of urethane and siloxane, polyether type polyurethane, etc., or these substances or physiologically active substances such as heparin and urokinase are applied to the surface. It is also possible to use a material coated with a hydrophilic material such as a special C-cohevarinized hydrophilic material.
中間チューブ２及び先端カテーテル４にはＸ線造影性粉
末などをブレンドしたものを材質とすることができる。The intermediate tube 2 and the distal catheter 4 may be made of a material blended with X-ray contrast powder or the like.
先端カテーテルにＸ線造影性を付与することによって、
血管内の先端カテーテル４の固定状況を容易に感知でき
、薬剤などの供給を確実にすることができる。By imparting X-ray contrast properties to the tip catheter,
The fixation status of the distal end catheter 4 within the blood vessel can be easily detected, and the supply of drugs and the like can be ensured.
本発明システムは具体的には、例えば、次のようにして
使用することができる。Specifically, the system of the present invention can be used in the following manner, for example.
使用例１
肝臓に悪性腫瘍のある患者に対して、金属チタ〉製容器
とシリコン製中間チューブとポリカーポ不−１−製コネ
イ７ターと造影剤入りポリウレタン製先端カテーテルか
らなる本発明システムを適用する。Usage Example 1 The system of the present invention, which consists of a container made of titanium metal, an intermediate tube made of silicone, a cone tube made of polycarbonate, and a tip catheter made of polyurethane containing a contrast medium, is applied to a patient with a malignant tumor in the liver. .
先端カテーテルの先を門脈の一支流に挿入固定し、同時
に、先端カテーテルの遠位部分にある薬剤リザーバーは
患者の体位変動の影響を受けない部分の皮下に固定し、
その上の皮膚を縫合して、注入システムを総て体内に埋
め込む。先端カテーテルの長さは殆どが血管に入るよう
に調節してコネクターで連結する。The tip of the tip catheter is inserted and fixed in one tributary of the portal vein, and at the same time, the drug reservoir in the distal part of the tip catheter is fixed subcutaneously in a part that is not affected by the patient's positional changes,
The skin above is sutured and the entire injection system is implanted inside the body. The length of the tip catheter is adjusted so that most of it enters the blood vessel, and the catheter is connected with a connector.
１〜２週間に一度の周期で皮膚下の薬剤リザバーの穿刺
部に体外より注射針を使って薬剤を注入することができ
る。Once every 1 to 2 weeks, a drug can be injected from outside the body into the puncture site of the drug reservoir under the skin using a syringe needle.
注入に際しては、皮膚及び注射針を消毒するだけで菌の
汚染は防止でき、６箇月以上体内に埋めて継続的薬液投
与しても血栓や薬剤による詰まりはなく円滑に治療する
ことができる。During injection, bacterial contamination can be prevented simply by disinfecting the skin and injection needle, and even if the drug is implanted in the body for more than six months and the drug solution is continuously administered, the treatment can be smoothly performed without clogging due to blood clots or drugs.
しかも、この患者について、薬剤注入システムを体内に
留置したままでＭＨＩ撮影で検査することかできる。Furthermore, this patient can be examined using MHI imaging while the drug injection system remains in the patient's body.
使用例２
２個の通路を有するチューブと２個の穿刺部と２個の保
存室を有する薬剤リザーバー容器からなる本発明のシス
テムの先端カテーテルを鎖骨下静脈を経て、中心静脈に
すすめて留置して、他端の静脈用薬剤リザーバーを前胸
部に作成した皮下ポケットに置く。Usage Example 2 The catheter at the tip of the system of the present invention, which consists of a tube with two passages, two puncture parts, and a drug reservoir container with two storage chambers, is advanced into the central vein via the subclavian vein and indwelled. Place the other end of the intravenous drug reservoir into the subcutaneous pocket created in the anterior chest.
薬剤リザーバーは筋膜に固定し、皮膚縫合を行い皮下に
埋め込む。The drug reservoir is fixed to the fascia, then skin sutured and implanted subcutaneously.
２個の穿刺部は体外から容易に確認でき、必要に応じて
、輸液及び薬剤を注入することができる。The two puncture sites can be easily confirmed from outside the body, and infusions and drugs can be injected as needed.
このような方式で１年以上薬剤及び輸液による栄養補給
をすることができる。In this way, it is possible to provide nutrition through drugs and infusions for more than one year.
［発明の効果］
本発明の薬剤注入システムは、長時間体内に留置しても
贋札及び血栓を起こす危険がない利点を有する上、各金
属部があるにもかかわらず、体内留置中にＭＲＩなどの
診断における強力な磁力によって先端カテーテルが脱離
するおそれもない利点がある。[Effects of the Invention] The drug injection system of the present invention has the advantage that there is no risk of counterfeit bills or blood clots even if it is left in the body for a long time, and even though it has metal parts, it cannot be used for MRI etc. while it is left in the body. This has the advantage that there is no risk of the distal catheter dislodging due to the strong magnetic force used in diagnosis.
第１図は本発明の薬剤注入システムの一実施例の断面区
であり、第２図はその平面図である。
図中の符号は、１；薬剤リザーバー ２；中間チューブ
、３；コネクター、４；先端カテーテル、５；中間チュ
ーブの連結端、６；先端カテーテルの連結端、７；自己
密閉型セプタムである。FIG. 1 is a sectional view of one embodiment of the drug injection system of the present invention, and FIG. 2 is a plan view thereof. Reference numerals in the figure are: 1; drug reservoir; 2; intermediate tube; 3; connector; 4; distal catheter; 5; connecting end of intermediate tube; 6; connecting end of distal catheter; 7; self-sealing septum.
Claims (1)
端カテーテルを必須構成要素とする体内埋め込み式カテ
ーテルにおいて、薬剤リザーバーは、上面に軟質材料製
穿刺部を有する非磁性金属製の流出口付き容器であって
、中間チューブは、組織適合性表面を有して流出口とコ
ネクターを連結し、コネクターは非磁性金属製又は硬質
プラスチック製であって中間チューブと先端カテーテル
を連結し、先端カテーテルは抗血栓性表面を有すること
を特徴とする薬剤注入システム。 ２ 薬剤リザーバー容器が金属チタン製である請求項１
記載の薬剤注入システム。 ３ 中間チューブの組織適合性表面がシリコンである請
求項１又は２記載の薬剤注入システム。 ４ 先端チューブの抗血栓性表面がポリウレタンである
請求項１、２又は３記載の薬剤注入システム。[Scope of Claims] 1. An implantable catheter comprising a drug reservoir, an intermediate tube, a connector, and a distal catheter as essential components, wherein the drug reservoir has an outlet made of a non-magnetic metal and has a puncture part made of a soft material on the upper surface. The container includes an intermediate tube having a tissue-compatible surface connecting the outlet and the connector, the connector being made of non-magnetic metal or hard plastic connecting the intermediate tube and the distal catheter, and the distal catheter having a A drug injection system characterized by having an antithrombotic surface. 2. Claim 1, wherein the drug reservoir container is made of titanium metal.
Drug injection system as described. 3. The drug injection system according to claim 1 or 2, wherein the tissue compatible surface of the intermediate tube is silicone. 4. The drug injection system according to claim 1, 2 or 3, wherein the antithrombotic surface of the tip tube is polyurethane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1337680A JP2602109B2 (en) | 1989-12-26 | 1989-12-26 | Drug injection system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1337680A JP2602109B2 (en) | 1989-12-26 | 1989-12-26 | Drug injection system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03195563A true JPH03195563A (en) | 1991-08-27 |
| JP2602109B2 JP2602109B2 (en) | 1997-04-23 |
Family
ID=18310950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1337680A Expired - Fee Related JP2602109B2 (en) | 1989-12-26 | 1989-12-26 | Drug injection system |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2602109B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0672914A1 (en) * | 1994-03-18 | 1995-09-20 | Olympus Optical Co., Ltd. | Device for use in combination with a magnetic resonance imaging apparatus |
| JP2007037626A (en) * | 2005-08-01 | 2007-02-15 | Fujikura Ltd | Equipment for delivering drug nontoxic to living body |
| JP2013510652A (en) * | 2009-11-17 | 2013-03-28 | シー・アール・バード・インコーポレーテッド | Overmolded access port including locking feature and identification feature |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2164559B1 (en) | 2007-06-20 | 2017-10-25 | Medical Components, Inc. | Venous access port with molded and/or radiopaque indicia |
| WO2009012385A1 (en) | 2007-07-19 | 2009-01-22 | Medical Components, Inc. | Venous access port assembly with x-ray discernable indicia |
| US9610432B2 (en) | 2007-07-19 | 2017-04-04 | Innovative Medical Devices, Llc | Venous access port assembly with X-ray discernable indicia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63252170A (en) * | 1987-04-08 | 1988-10-19 | 富士システムズ株式会社 | Body embedding type catheter equipped with reservoir |
| JPS6470076A (en) * | 1987-08-25 | 1989-03-15 | Shiirii Infuyuusetsudo Inc | Access device capable of being buried under the skin |
| JPH0385178A (en) * | 1989-08-29 | 1991-04-10 | Olympus Optical Co Ltd | Medicine injection apparatus |
-
1989
- 1989-12-26 JP JP1337680A patent/JP2602109B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63252170A (en) * | 1987-04-08 | 1988-10-19 | 富士システムズ株式会社 | Body embedding type catheter equipped with reservoir |
| JPS6470076A (en) * | 1987-08-25 | 1989-03-15 | Shiirii Infuyuusetsudo Inc | Access device capable of being buried under the skin |
| JPH0385178A (en) * | 1989-08-29 | 1991-04-10 | Olympus Optical Co Ltd | Medicine injection apparatus |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0672914A1 (en) * | 1994-03-18 | 1995-09-20 | Olympus Optical Co., Ltd. | Device for use in combination with a magnetic resonance imaging apparatus |
| US5738632A (en) * | 1994-03-18 | 1998-04-14 | Olympus Optical Co., Ltd. | Device for use in combination with a magnetic resonance imaging apparatus |
| JP2007037626A (en) * | 2005-08-01 | 2007-02-15 | Fujikura Ltd | Equipment for delivering drug nontoxic to living body |
| JP2013510652A (en) * | 2009-11-17 | 2013-03-28 | シー・アール・バード・インコーポレーテッド | Overmolded access port including locking feature and identification feature |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2602109B2 (en) | 1997-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0366814B1 (en) | Subcutaneously implanted catheter assembly | |
| US5041098A (en) | Vascular access system for extracorporeal treatment of blood | |
| EP0746381B1 (en) | Implantable access devices | |
| US5944688A (en) | Implantable hemodialysis access port assembly | |
| CA2229370C (en) | Catheter | |
| AU764894C (en) | Implantable device for access to a treatment site | |
| US20020072706A1 (en) | Transluminal drug delivery catheter | |
| US6299609B1 (en) | Methods and apparatus for inhibiting infection of subcutaneously implanted devices | |
| US20100256487A1 (en) | Micro central line vascular access catheter and method of use | |
| WO1996034647A1 (en) | Implantable catheter and method of use | |
| KR20150016970A (en) | Catheter systems and methods useful for cell therapy | |
| JP2011512885A (en) | Implantable access for fluid withdrawal and / or return | |
| US20090306606A1 (en) | Catheter hub assembly with vascular access port | |
| JPH03195563A (en) | Chemical injection system | |
| WO2002055130A2 (en) | Transluminal drug delivery catheter | |
| CN113599620A (en) | Implantable drug delivery device | |
| JPH0736661Y2 (en) | catheter | |
| US20070073239A1 (en) | Catheter device | |
| JP2004503336A (en) | Apparatus and method for injecting liquid into a catheter | |
| JP3137360B2 (en) | Chemical injection port | |
| CN220513252U (en) | Catheter for hepatic artery perfusion chemotherapy | |
| JPH0669496B2 (en) | Chemical injection port | |
| JP2908503B2 (en) | Chemical injection port | |
| JPH06277298A (en) | Embedded medicine liquid injection port | |
| JP2821753B2 (en) | catheter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |